Clinical Characteristics and Outcomes of Patients Requiring Vasopressor Support in the critical care settings

Main Article Content

Muhammad Saleem Awan
Munawar Ali Awan
Masab Hanif
Wajahat Sami Malik
Muhammad Iqbal Qasim
Nadeem Gohar

Keywords

Vasopressor therapy, intensive care unit, septic shock, circulatory shock, norepinephrine, ICU mortality, acute kidney injury, critical care

Abstract

Background: Vasopressor therapy is an essential component of the management of critically ill patients with circulatory shock in the intensive care unit (ICU). The requirement for vasopressor support is generally associated with severe illness, multiple organ dysfunction, prolonged ICU stay, and increased mortality. Limited data are available regarding the clinical characteristics and outcomes of patients receiving vasopressors in resource-limited healthcare settings. Objective: To evaluate the clinical characteristics, indications, complications, and outcomes of patients requiring vasopressor support in the ICU of District Headquarter (DHQ) Hospital Mansehra. Methodology: A hospital-based prospective observational study was conducted in the ICU of DHQ Hospital Mansehra, Pakistan, over a six-month period from 15 February 2023 to 30 August 2023. A total of 250 consecutive adult patients requiring vasopressor therapy were enrolled. Demographic characteristics, clinical variables, vasopressor utilization, complications, and patient outcomes were prospectively recorded using a standardized data collection form. Data were analyzed using IBM SPSS Statistics version 25.0. Continuous and categorical variables were analyzed using appropriate statistical tests, and multivariable logistic regression was performed to identify independent predictors of ICU mortality. A p-value <0.05 was considered statistically significant. Results: The mean age of the patients was 56.8 ± 17.2 years, and 59.2% were male. Septic shock was the most common indication for vasopressor therapy (43.2%), followed by cardiogenic shock (20.8%) and hypovolemic shock (15.2%). Norepinephrine was the most frequently administered vasopressor (79.2%). Mechanical ventilation was required in 68.8% of patients, while 16.4% underwent renal replacement therapy. Vasopressor-related complications occurred in 39.2% of patients, with acute kidney injury (23.2%) being the most common complication. The overall ICU mortality was 35.6%. Non-survivors had significantly higher SOFA and APACHE II scores, longer duration of vasopressor therapy, greater need for mechanical ventilation, and a higher incidence of acute kidney injury compared with survivors (p <0.001). Conclusion: Patients requiring vasopressor support in the ICU experience considerable morbidity and mortality, with septic shock being the leading indication for therapy. Higher illness severity, prolonged vasopressor use, mechanical ventilation, and acute kidney injury were significant predictors of poor outcomes. Early recognition of shock and prompt evidence-based hemodynamic management may improve survival in critically ill patients.

Abstract 0 | PDF Downloads 0

References

1. Livesey M, Jauregui JJ, Hamaker MC, Pensy RA, Langhammer CG, Eglseder WA. Management of vasopressor induced ischemia. Journal of Orthopaedics. 2020 Nov 1;22:497-502.
2. Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Critical Care. 2018 Jul 6;22(1):174.
3. Smischney NJ, Demirci O, Ricter BD, Hoeft CC, Johnson LM, Ansar S, Kashyap R. Vasopressor use as a surrogate for post-intubation hemodynamic instability is associated with in-hospital and 90-day mortality: a retrospective cohort study. BMC research notes. 2015 Sep 15;8(1):445.
4. Convertino VA, Lye KR, Koons NJ, Joyner MJ. Physiological comparison of hemorrhagic shock and V˙ O2max: a conceptual framework for defining the limitation of oxygen delivery. Experimental Biology and Medicine. 2019 May;244(8):690-701.
5. Scheeren TW, Bakker J, De Backer D, Annane D, Asfar P, Boerma EC, Cecconi M, Dubin A, Dünser MW, Duranteau J, Gordon AC. Current use of vasopressors in septic shock. Annals of intensive care. 2019 Jan 30;9(1):20.
6. Zimmerman J, Lee JP, Cahalan M. Vasopressors and inotropes. Pharmacology and Physiology for Anesthesia. 2019 Jan 1:520-34.
7. Auchet T, Regnier MA, Girerd N, Levy B. Outcome of patients with septic shock and high-dose vasopressor therapy. Annals of intensive care. 2017 Jan 1;7(1):43.
8. Font MD, Thyagarajan B, Khanna AK. Sepsis and Septic Shock–Basics of diagnosis, pathophysiology and clinical decision making. Medical Clinics. 2020 Jul 1;104(4):573-85.
9. Russell JA. Vasopressor therapy in critically ill patients with shock. Intensive care medicine. 2019 Nov;45(11):1503-17.
10. Hidalgo DC, Patel J, Masic D, Park D, Rech MA. Delayed vasopressor initiation is associated with increased mortality in patients with septic shock. Journal of Critical Care. 2020 Feb 1;55:145-8.
11. Beck V, Chateau D, Bryson GL, Pisipati A, Zanotti S, Parrillo JE, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Timing of vasopressor initiation and mortality in septic shock: a cohort study. Critical care. 2014 May 12;18(3): R97.
12. Schultz MJ, Dünser MW, Dondorp AM, Adhikari NK, Iyer S, Kwizera A, Lubell Y, Papali A, Pisani L, Riviello ED, Angus DC. Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. Sepsis management in resource-limited settings. 2019 Feb 9:1-24.
13. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive care medicine. 2021 Nov;47(11):1181-247.
14. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama. 2016 Feb 23;315(8):801-10.
15. Vincent JL, De Backer D. Circulatory shock. New England Journal of Medicine. 2013 Oct 31;369(18):1726-34.
16. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT. Angiotensin II for the treatment of vasodilatory shock. New England Journal of Medicine. 2017 Aug 3;377(5):419-30.
17. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, Lemeshow S, Osborn T, Terry KM, Levy MM. Time to treatment and mortality during mandated emergency care for sepsis. New England Journal of Medicine. 2017 Jun 8;376(23):2235-44.

Most read articles by the same author(s)